Three C Study suggests 28-day efficacy window, 600-mg dose
‘A gateway to...a new range of therapies for atherosclerosis’
Beyond the headlines on CANTOS, REVEAL, COMPASS
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy